L. Borgstrom et al., THE INHALATION DEVICE INFLUENCES LUNG DEPOSITION AND BRONCHODILATING EFFECT OF TERBUTALINE, American journal of respiratory and critical care medicine, 153(5), 1996, pp. 1636-1640
Citations number
32
Categorie Soggetti
Emergency Medicine & Critical Care","Respiratory System
The development of new inhalation devices for asthma drugs raises the
issue of the relationship between pulmonary deposition and therapeutic
effect of inhaled drugs in patients with obstructive lung diseases. W
e thus conducted a randomized, double-blind and double-dummy, four-per
iod crossover study in 13 patients with moderate asthma (mean age 36 y
r; FEV(1) 59% of predicted), who inhaled 0.25 and 0.5 mg terbutaline s
ulphate on separate occasions either via a pressurized metered dose in
haler (pMDI) or Turbuhale(R) (TBH). Pulmonary deposition was 8.1 +/- 2
.7% and 8.3 +/- 2.3%, respectively, of the nominal dose for pMDI and 1
9.0 +/- 7.3%, and 22.0 +/- 8.1% for TBH. The FEV(1) increase after 0.2
5 mg terbutaline sulphate via TBH was significantly greater than after
0.25 mg via pMDI. No significant differences in FEV(1) increase were
observed between 0.25 mg via TBH, 0.5 mg via pMDI, or 0.5 mg via TBH.
Other lung function variables showed similar dose- and device-related
changes. We concluded that: (1) the dose of terbutaline sulphate depos
ited in the lungs is dependent on which inhalation system is used; (2)
TBH delivers about twice the amount of drug to the lungs as the pMDI;
and (3) the observed difference in deposition is reflected in the bro
nchodilating effect.